BridgeMD
New treatment option for First Episode Psychosis
Official title Recovery With Exogenous Ketones and Antipsychotics
ClinicalTrials.gov ID: NCT07122531
What this study is testing
- What it's testing
- The RECAP project will evaluate the clinical and metabolic effects of adding exogenous ketones to antipsychotic (AP) treatment in young adults with a first episode of psychosis (FEP). FEP requires early intervention to limit relapse, chronic symptoms, cognitive decline, and reduced life expectancy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 35
You may be able to join if
- Referred or self-referred to the PEP Clinic of the Estrie region, either as an outpatient or inpatient.
- Currently receiving a second- or third-generation antipsychotic at a stable dose for at least 4 weeks.
- Able to read and communicate in French or English.
- Capable of understanding and signing the informed consent form.
You likely can't join if
- Pregnancy, childbirth within the past 6 months, or breastfeeding.
- any use of MCT oil, ketone salts, or a ketogenic diet within the past year.
- Previous diagnosis of type I or type II diabetes.
- Uncontrolled acute suicidal ideation at the time of inclusion in the PEP clinic.
- Other conditions that may interfere with participation, as determined by the qualified physician.
- Pancreatitis (inflammation of the pancreas) or liver failure.
See the full eligibility criteria
- Referred or self-referred to the PEP Clinic of the Estrie region, either as an outpatient or inpatient.
- Currently receiving a second- or third-generation antipsychotic at a stable dose for at least 4 weeks.
- Able to read and communicate in French or English.
- Capable of understanding and signing the informed consent form.
- Pregnancy, childbirth within the past 6 months, or breastfeeding.
- any use of MCT oil, ketone salts, or a ketogenic diet within the past year.
- Previous diagnosis of type I or type II diabetes.
- Uncontrolled acute suicidal ideation at the time of inclusion in the PEP clinic.
- Other conditions that may interfere with participation, as determined by the qualified physician.
- Pancreatitis (inflammation of the pancreas) or liver failure.
- Metabolic condition affecting fat metabolism or inherited carnitine deficiency and its related enzymes.
- Porphyria.
- Pyruvate kinase deficiency.
- Neurodevelopmental disorder of unknown etiology or rare genetic disease.
The study team makes the final eligibility decision.
Where it's taking place
- Sherbrooke, Quebec, Canada
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 35 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.